The effect of esketamine on perioperative anxiety and depressive symptoms in patients undergoing total hysterectomy.

Abstract

<h4>Aim</h4>This study aimed to evaluate the effect of esketamine on perioperative anxiety and depressive symptoms, acute stress reaction, and serum neurotransmitters in patients undergoing total hysterectomy.<h4>Methods</h4>Clinical data of 120 patients undergoing total hysterectomy from May 2020 to June 2021 were retrospectively analyzed and divided into group C (3 mL of saline administered intravenously 10 min before surgical excision, 65 patients) or group K (0.5 mg/kg of esketamine administered intravenously 10 min before surgical excision, 55 patients).<h4>Results</h4>Acute stress reaction, depression, and anxiety; and myeloperoxidase levels were lower while serum dopamine, 5-hydroxytryptamine, neuropeptide, as well as brain-derived neurotrophic factor levels were higher in group K than those in group C at 12 h postoperatively (p < 0.05). Additionally, analgesic effect and postoperative fatigue at 3 h and 12 h postoperatively were lower in group K than those in group C (p < 0.05). The incidence of adverse reactions in group K (14.55%) did not differ significantly from group C (4.62%) (p > 0.05).<h4>Conclusions</h4>In summary, as a preventive measure for patients undergoing total hysterectomy, esketamine can reduce perioperative anxiety and depression, result in good analgesic and sedative effects without significantly increasing adverse effects.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords